DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Midamor is a drug marketed by Padagis Us and is included in one NDA.
The generic ingredient in MIDAMOR is amiloride hydrochloride. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the amiloride hydrochloride profile page.
A generic version of MIDAMOR was approved as amiloride hydrochloride by PAR PHARM on January 22nd, 1986.
Recent Clinical Trials for MIDAMOR
Identify potential brand extensions & 505(b)(2) entrants
|Center for Addiction and Mental Health||Early Phase 1|
|Venkata Yellepeddi||Early Phase 1|
|University of Pittsburgh||Phase 0|
Pharmacology for MIDAMOR
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Padagis Us||MIDAMOR||amiloride hydrochloride||TABLET;ORAL||018200-001||Approved Prior to Jan 1, 1982||AB||RX||Yes||No||⤷ Free Forever Trial||⤷ Free Forever Trial||⤷ Free Forever Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|